EcoDrugPlus

Integrin Subunit Alpha V

Ensembl ID : ENSBTAG00000019929
Gene Symbol: ITGAV
24 Enzyme and pathways 5 Cross references
256 Possible Orthologues:

Integrin Subunit Beta 1

Ensembl ID : ENSBTAG00000015910
Gene Symbol: ITGB1
36 Enzyme and pathways 5 Cross references
313 Possible Orthologues:

Integrin Subunit Beta 3

Ensembl ID : ENSBTAG00000009987
Gene Symbol: ITGB3
28 Enzyme and pathways 4 Cross references
280 Possible Orthologues:

Integrin Subunit Beta 5

Ensembl ID : ENSBTAG00000013755
Gene Symbol: ITGB5
18 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSBTAG00000009080
Gene Symbol: ITGB6
9 Enzyme and pathways 5 Cross references
217 Possible Orthologues:

Integrin Subunit Beta 7

Ensembl ID : ENSBTAG00000018993
Gene Symbol: ITGB7
5 Enzyme and pathways 5 Cross references
171 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSBTAG00000003709
Gene Symbol: ITGB8
8 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Intercellular Adhesion Molecule 1

Ensembl ID : ENSBTAG00000010303
Gene Symbol: ICAM1
5 Cross references
86 Possible Orthologues:

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSBTAG00000021105
Gene Symbol: IRAK4
10 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Interleukin 5

Ensembl ID : ENSBTAG00000031235
Gene Symbol: IL5
5 Cross references
103 Possible Orthologues:

Interleukin 6

Ensembl ID : ENSBTAG00000014921
Gene Symbol: IL6
15 Enzyme and pathways 5 Cross references
174 Possible Orthologues:

Interstitial Collagenase-Like

Ensembl ID : ENSBTAG00000015818
Gene Symbol: LOC112441463
4 Cross references
346 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).